Is Wall Street Bullish or Bearish on Zimmer Biomet Stock?

Barchart
Barchart kaynağında aç
Is Wall Street Bullish or Bearish on Zimmer Biomet Stock?

Valued at $19.2 billion by market cap, Zimmer Biomet Holdings, Inc. (ZBH) is a global medical technology company headquartered in Warsaw, Indiana. The company designs, manufactures, and markets a broad range of orthopedic medical devices, surgical products, and digital healthcare technologies used to treat musculoskeletal conditions and injuries. Its products help patients with joint disorders, bone fractures, sports-related injuries, and other conditions affecting bones, joints, and supporting soft tissues. Zimmer Biomet operates in more than 25 countries, with its products and solutions used in over 100 countries worldwide.

Shares of the medical device giant have fared better than the broader market over the past year. ZBH has surged 12.8% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 10.1%. ZBH stock has gained 21.2% over the past six months, compared to the SPX’s marginal rise. 

More Top Stocks Daily: Go behind Wall Street’s hottest headlines with Barchart’s Active Investor newsletter.

 

Narrowing the focus, ZBH has also surpassed the iShares U.S. Medical Devices ETF (IHI), which has declined 7,6% over the past year and has gained 18.8% over the past six months. 

www.barchart.com

On Nov. 4, Zimmer Biomet released its Q3 2026 earnings, and its shares rose 3.5%. It reported revenue of $2.063 billion, up 3.1% year over year on a reported basis and 3.7% on a constant-currency basis. Revenue exceeded analyst expectations of approximately $2.04 billion. Adjusted diluted EPS came in at $1.90, unchanged from the prior-year quarter but above the consensus estimate of $1.88.

For the current fiscal year, ending in December, analysts expect ZBH’s EPS to grow 4.4% to $8.56 on a diluted basis. The company’s earnings surprise history is impressive. It beat the consensus estimate in each of the last four quarters.

Among the 29 analysts covering ZBH stock, the consensus is a “Moderate Buy.” That’s based on seven “Strong Buy” ratings, one “Moderate Buy,” 20 “Holds,” and one “Strong Sell.”

www.barchart.com

This consensus is bullish than three months ago, when the stock had an overall “Hold” rating.  

Wells Fargo upgraded Zimmer Biomet to “Overweight” from “Equal Weight” and raised its price target to $123 from $113 on November 17. 

The mean price target of $114.88 represents a 13.3% premium to ZBH’s current price levels. The Street-high price target of $140 suggests an upside potential of 38.1%.


On the date of publication, Kritika Sarmah did not directly have a position in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.

 

More news from Barchart

Shorting ConocoPhillips Puts and Put Credit Spreads Are Attractive Income Plays The $70 Million Reason Cathie Wood Can't Stop Buying Rocket Lab Stock What is the 2027 Outlook for the Grains Sector? Why You Should Buy the Pullback in Palantir Stock Now